文献速递免疫规划

用于多价免疫抗B群脑膜炎奈瑟菌的自扩增mRNA疫苗的模块化设计

Modular design of a self-amplifying mRNA vaccine for multivalent immunization against Neisseria meningitidis B.
PubMed 文献 · Vaccine · 2025-11-07

本研究构建并评价了两种多价自扩增mRNA(SAM)疫苗设计:将四种抗原串联于单一融合SAM构建体,或将四种单抗原SAM分别封装后混合(PreMix)或分别封装后混合(PostMix)。单抗原混合递送方案抗原表达和免疫原性更优,PreMix在5 μg剂量下血清杀菌试验滴度为1:256,明显高于串联构建体的1:32。

要点

  • 单抗原混合递送SAM疫苗的抗原表达和免疫原性优于四抗原串联融合设计。
  • PreMix在5 μg剂量下血清杀菌试验滴度为1:256,串联构建体SAM-SP2为1:32。
  • 1 μg低剂量即可诱导强效体液和细胞免疫应答,显示SAM平台具有剂量节省潜力。

核心结论

  • 单抗原混合递送的自扩增mRNA疫苗在免疫效果和工艺可行性方面均显示明显优势,为多价细菌mRNA疫苗的设计和平台开发提供了通用路径。

研究设计与样本

  • 本研究构建并评价了两种多价自扩增mRNA(SAM)疫苗设计:第一种将四种抗原串联于单一融合SAM构建体;第二种采用四个分别编码单一抗原的SAM构建体,在脂质纳米颗粒(LNP)封装前等质量混合(PreMix)或分别封装后混合(PostMix)。

主要发现

  • 串联构型体外表达有限,但仍在小鼠中诱导免疫应答。
  • 单抗原混合递送方案显示更优的抗原表达和免疫原性。
  • PreMix制剂(SAM-PreMix)在5 μg剂量下血清杀菌试验(SBA)滴度为1:256,明显高于串联构建体(SAM-SP2)的1:32。
  • 即使在1 μg低剂量下也诱导了强效体液和细胞免疫应答,显示SAM平台的剂量节省潜力。
  • PreMix与PostMix的免疫效果相当,但前者在可制造性和标准化方面具有更多工艺优势。

关键数值与推荐

  • PreMix制剂(SAM-PreMix)在5 μg剂量下SBA滴度为1:256,串联构建体(SAM-SP2)为1:32。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neisseria meningitidis group B (MenB) continues to pose challenges to vaccine development due to its antigenic diversity and immune escape mechanisms. Self-amplifying mRNA (SAM) vaccine platforms offer advantages such as long-lasting expression and flexible antigen combinations, which provide new strategies for tackling complex bacterial pathogens. In this study, we constructed and evaluated two multivalent SAM vaccine designs. The first design involved linking four antigens-factor H binding protein (fHbp), Neisseria Heparin-Binding Antigen (NHBA), Neisserial adhesin A (NadA), and Porin A (PorA)-in tandem within a single fusion SAM construct. The second strategy employed four individual SAM constructs, each encoding a single antigen, and these were delivered either by mixing equal masses of the four SAMs before lipid nanoparticle (LNP) encapsulation (PreMix) or by mixing the individually encapsulated mRNA-LNPs (PostMix). Systematic evaluation revealed that the tandem configuration exhibited limited in vitro expression but still induced immune responses in mice. In contrast, the single-antigen mixed-delivery approach demonstrated superior antigen expression and immunogenicity. The PreMix formulation (SAM-PreMix) elicited a serum bactericidal assay (SBA) titer of 1:256 at a 5 μg dose, which was markedly higher than the 1:32 titer observed with the tandem construct (SAM-SP2). Moreover, strong humoral and cellular immune responses were induced even at a low dose of 1 μg, underscoring the dose-sparing potential of the SAM platform. While the immunization effects of PreMix and PostMix are comparable, the former has more process advantages regarding manufacturability and standardization. Our technology demonstrates significant advantages in both immunization efficacy and process feasibility, offering a universal pathway for the design and platform development of multivalent bacterial mRNA vaccines with potential applications in research related to other complex bacterial pathogens.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chen G, Chen G, Wang S, et al. Modular design of a self-amplifying mRNA vaccine for multivalent immunization against Neisseria meningitidis B. Vaccine. 2025. PMID: 41205400. doi:10.1016/j.vaccine.2025.127964

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。